Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Capital Expenditures: 2021-2024

Historic Capital Expenditures for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Dec 2024 value amounting to $34,000.

  • Centessa Pharmaceuticals' Capital Expenditures rose 588.24% to $234,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $339,000, marking a year-over-year increase of 194.78%. This contributed to the annual value of $34,000 for FY2024, which is 79.88% down from last year.
  • As of FY2024, Centessa Pharmaceuticals' Capital Expenditures stood at $34,000, which was down 79.88% from $169,000 recorded in FY2023.
  • Centessa Pharmaceuticals' Capital Expenditures' 5-year high stood at $1.1 million during FY2022, with a 5-year trough of $34,000 in FY2024.
  • For the 3-year period, Centessa Pharmaceuticals' Capital Expenditures averaged around $446,667, with its median value being $169,000 (2023).
  • In the last 5 years, Centessa Pharmaceuticals' Capital Expenditures skyrocketed by 511.29% in 2022 and then plummeted by 85.14% in 2023.
  • Yearly analysis of 4 years shows Centessa Pharmaceuticals' Capital Expenditures stood at $186,000 in 2021, then spiked by 511.29% to $1.1 million in 2022, then crashed by 85.14% to $169,000 in 2023, then slumped by 79.88% to $34,000 in 2024.